Tingting Hong1, Di Shen1, Xiaoping Chen1, Dongyan Cai1, Xiaohong Wu1, Dong Hua2. 1. Department of Medical Oncology, Affiliated Hospital of Jiangnan University and Fourth People's Hospital of Wuxi, 200 Huihe Road, Wuxi, China. 2. Department of Medical Oncology, Affiliated Hospital of Jiangnan University and Fourth People's Hospital of Wuxi, 200 Huihe Road, Wuxi, China. Electronic address: 553273569@qq.com.
Abstract
BACKGROUD: To better identify patients with high mortality risk, we developed a systematic inflammation index (IPI) based on neutrophil to lymphocyte ratio (NLR) and albumin. METHODS: The performance of pretreatment IPI was evaluated in patients with surgically resected non-metastatic colorectal cancer. IPI was predefined and compared with Glasgow Prognostic Score (GPS)/modified GPS in terms of discrimination and calibration abilities. RESULTS: In multivariate analysis, patients with an IPI of 1 or 2 had 1.68(95%CI:1.15-2.44) or 3.56(95%CI:2.12-5.98)-fold increased cancer specific mortality risk(CSMR) respectively in comparison to patients with an IPI of 0. The prognostic significance was independent of tumor locations and nodal status. Compared with the GPS/mGPS, IPI had the higher c statistics and lower Akaike Information Criterion. IPI showed good calibration in predicting 1-year, 3-year and 5-year CSMR. CONCLUSIONS: IPI is readily available, independently prognostic and may reflect the host inflammation, immune and nutritional status that could have impact on cancer progression.
BACKGROUD: To better identify patients with high mortality risk, we developed a systematic inflammation index (IPI) based on neutrophil to lymphocyte ratio (NLR) and albumin. METHODS: The performance of pretreatment IPI was evaluated in patients with surgically resected non-metastatic colorectal cancer. IPI was predefined and compared with Glasgow Prognostic Score (GPS)/modified GPS in terms of discrimination and calibration abilities. RESULTS: In multivariate analysis, patients with an IPI of 1 or 2 had 1.68(95%CI:1.15-2.44) or 3.56(95%CI:2.12-5.98)-fold increased cancer specific mortality risk(CSMR) respectively in comparison to patients with an IPI of 0. The prognostic significance was independent of tumor locations and nodal status. Compared with the GPS/mGPS, IPI had the higher c statistics and lower Akaike Information Criterion. IPI showed good calibration in predicting 1-year, 3-year and 5-year CSMR. CONCLUSIONS:IPI is readily available, independently prognostic and may reflect the host inflammation, immune and nutritional status that could have impact on cancer progression.
Authors: Stephen Gowing; Laura Baker; Alexandre Tran; Zach Zhang; Hilalion Ahn; Jelena Ivanovic; Caitlin Anstee; Emma Grigor; Sebastien Gilbert; Donna E Maziak; Farid Shamji; Sudhir Sundaresan; Patrick James Villeneuve; Andrew J E Seely Journal: Lung Date: 2020-10-09 Impact factor: 2.584